Ending the era of $100,000 cancer drugs

05:16 EDT 11 Aug 2017 | Pharmafile

Paul Workman, Chief Executive and President of the Institute of Cancer Research, examines the spiralling cost of cancer treatments and what can be done to bring them down to a manageable level whilst ensuring patients receive the best treatment.

Something has to change. We cannot continue putting up with new cancer drugs costing up to, and in excess of, $100,000 (£80,000). This is unsustainable and we need to be thinking hard about how we can make prices come down.

read more

Original Article: Ending the era of $100,000 cancer drugs


More From BioPortfolio on "Ending the era of $100,000 cancer drugs"

Quick Search

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...